ZFP36L1 and neoplasm: Consistent with our data above, ZFP36L1 was expressed in the inflammatory tumor cell subpopulation that emerged after cisplatin recurrence while its expression was largely absent in the ASCL1/INSM1-high neuroendocrine populations (Fig. 6h, i and Supplementary Fig. 13a–d).